A Phase 4 interventional study of Angiotensin II in Vasodilatory Hypotension During or After Cardiac Surgery, sponsored by University of Maryland St. Joseph Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by University of Maryland St. Joseph Medical Center · Phase 4, Interventional, and Treatment
The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery. Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.
381 studies on the registry are indexed under Aneurysm; 78 are open to participants now.
This study's planned enrollment of 100 is above the median of 46 across 235 interventional studies indexed under Aneurysm.
Browse Aneurysm studies →University of Maryland St. Joseph Medical Center is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Angiotensin II
Drug: Angiotensin II
Angiotensin II: Starting dose of 2.5 ng/kg/min administered IV; may dose escalate up to 80 ng/kg/min in order to achieve a MAP of 65 mmHg or higher in the first 3 hours. After 3 hours, may escalate dose up to 40 ng/kg/min in order to achieve a MAP of 65 mmHg. Dose titration in increments of 10 ng/kg/min every 2 minutes.
Incidence of postoperative acute kidney injury, atrial fibrillation
The primary endpoint will be measured by comparing the incidence of new-onset atrial fibrillation or acute kidney injury
Time frame: 28 days
Hours on Vasopressors
Time frame: 28 days
Total IVF
Time frame: 28 days
ICU LOS
Time frame: 28 days
Postoperative LOS
Time frame: 28 days
Any major STS complication
Time frame: 28 days
30-day mortality
Time frame: 30 days
Cost
Time frame: 28 days
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Angiotensin II
University of Maryland St. Joseph Medical Center